Dermatology CME Courses

Board Vitals offers hundreds of Dermatology Questions targeted to the ABDERM and MOC:PQRS exam. Our question bank is specifically designed around difficult questions, with detailed explanations around the correct answer.

The logistics – the Derm exam is a long exam (8 hours) and has a fairly middle of the road pass rate compared to the other specialties. (90% pass rate average over the past several years) There are two major sections – the Dermatopathology and Virtual Dermatopathology Section, and the written Multiple Choice Section (300 Questions).

The vast majority of students that score at least 60% correct on our Dermatology practice questions pass the board exam. It is very rare for someone to exceed the average - 62% threshold on our exam - and not pass the boards. When using our question bank, a primary goal should be focusing on not performing in the lowest 20% of test takers. (Each question comes with an individual average score)<

By the end of the session the participant will be able to:

• Describe the role of the immune system in cancer and cancer therapy in metastatic melanoma.
• Distinguish between the different forms of therapy presently approved for metastatic melanoma and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
• Describe emerging (investigational) therapies for metastatic melanoma
• Describe the challenges and barriers to care associated with treating patients with metastatic melanoma

Learning Objectives:

• Summarize the most impactful findings presented at ASCO 2017 relating to Metastatic Melanoma and apply them to patient cases, taking into account any relevant barriers to care.
• Additional objectives to be dictated by clinical content

By the end of the session the participant will be able to:

• Describe the role of the immune system in cancer and cancer therapy in metastatic melanoma.
• Distinguish between the different forms of therapy presently approved for metastatic melanoma and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
• Describe emerging (investigational) therapies for metastatic melanoma
• Describe the challenges and barriers to care associated with treating patients with metastatic melanoma